Agios Pharmaceuticals, Inc.
AGIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | -0.07 | 0.20 | 0.04 |
| FCF Yield | -20.97% | -23.97% | -20.43% | -20.79% |
| EV / EBITDA | -4.40 | -3.18 | -3.90 | -5.57 |
| Quality | ||||
| ROIC | -24.99% | -44.28% | -32.70% | -27.03% |
| Gross Margin | 88.59% | 64.57% | 88.03% | 0.00% |
| Cash Conversion Ratio | -0.58 | 0.84 | 1.34 | 1.14 |
| Growth | ||||
| Revenue 3-Year CAGR | 36.85% | – | – | -100.00% |
| Free Cash Flow Growth | -31.80% | 5.50% | 23.90% | -35.13% |
| Safety | ||||
| Net Debt / EBITDA | 0.05 | 0.04 | 0.14 | 0.31 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.15 | 0.50 | 0.20 | 1.16 |
| Cash Conversion Cycle | 1,002.71 | 395.25 | -2,112.04 | -9.91 |